Targeting Nanoparticles for Drug Delivery to Renal Graft Endothelium during Ex Vivo Normothermic Perfusion
Targeting Nanoparticles for Drug Delivery to Renal Graft Endothelium during Ex Vivo Normothermic Perfusion
批准号:
9164300
负责人:
JORDAN S POBER
金额:
$25.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-18 至 2017-06-30
关键词:
AcuteAdaptor Signaling ProteinAddressAllograftingAminesAntibodiesBindingBloodBlood VesselsBody TemperatureBrain DeathCell Culture TechniquesCell DeathCell LineCellsClinicDevelopmentDrug Delivery SystemsElementsEncapsulatedEndothelial CellsEndotheliumEstersFailureFormulationFrequenciesFundingGene ExpressionGlycolic-Lactic Acid PolyesterGoalsGraft RejectionGraft SurvivalGrantHumanImmune systemImmunosuppressionIn VitroIndividualInflammationInflammatoryInjuryKidneyKidney TransplantationLinkLiving DonorsMediatingMediator of activation proteinMetabolicMethodsMicrofluidic MicrochipsMolecular TargetOrganOrgan DonorOrgan TransplantationOutcomePerfusionPerioperativePolymersPopulationProceduresProcessProductionPumpRecruitment ActivityReperfusion InjuryResourcesRiskSeveritiesSmall Interfering RNASolidSpecificityStagingStudy SectionSystemTNF geneTNFRSF1A geneTRADD geneTestingTissuesTransplantationTumor Necrosis Factor ReceptorUnited States National Institutes of HealthUniversitiesWorkallograft rejectionantibody conjugatebiodegradable polymercellular targetingclinical applicationcytokinedelayed graft functiondesignimmunogenicityimplantationimprovedinnovationinterestkidney allograftknock-downnanoparticleneutrophilnovelnovel therapeuticsprotein expressionrenal ischemiaresearch studyresponseuptake
中文摘要
项目总结
排斥反应仍然是同种异体移植物丢失的主要原因,其频率和严重程度因围术期的原因而加剧。
移植物手术缺血再灌注损伤(IRI)。对这种联系的机械解释是,IRI
移植物内皮细胞(EC)增强其刺激宿主免疫系统的能力,加剧
拒绝。体外常温灌流(EVNP)是一种实验性的方法,最先用于肾脏
由我们在剑桥大学的合作者进行的移植,通过改善
组织的代谢状态。我们假设这一过程可以同时用于改善IRI
并在器官植入前通过向移植物EC输送siRNA来减少排斥反应。我们已经选择了肿瘤
作为siRNA分子靶点的肿瘤坏死因子受体1(TNFR1)及其关键接头蛋白Tradd
这些实验中的敲除是因为这些分子介导了EC的肿瘤坏死因子反应
促进炎症和细胞死亡,这是肾脏IRI的重要过程,但这一R21的目标仅限于
SiRNA敲除效果的优化。目前,siRNA在临床上的传递受到不完全的限制
击倒的程度和持续时间很短,因为无法有效地定位感兴趣的细胞,以及
不适当的细胞目标。在这里,我们建议进行原则证明研究,以证明抗体-
共轭、可降解的聚合物纳米颗粒(NP)可以被设计来克服这些限制。我们的
具体目标是:(1)优化多功能、可降解NPs的配方,使用已建立的和
用于siRNA负载、siRNA缓释和mAb偶联的新型可降解聚合物;(2)鉴定
培养人结合和摄取结合NP的最佳EC特异性单抗或单抗组合
耶鲁大学的EC在体外流动,接受EVNP的已故供者肾脏,后者将由
我们在剑桥大学的合作者拥有独立于此R21应用程序的资源;
成功完成这些目标将为创新方法提供概念验证,以减少
通过体外靶向移植物的新型药物输送载体进行同种异体排斥反应,使宿主免受
需要过度的免疫抑制。
英文摘要
PROJECT SUMMARY
Rejection remains the major cause of allograft loss and its frequency and severity are exacerbated by peri-
operative ischemia/reperfusion injury (IRI) of the graft. A mechanistic explanation of this connection is that IRI
of graft endothelial cells (EC) enhances their ability to stimulate the host immune system, exacerbating
rejection. Ex vivo normothermic perfusion (EVNP) is an experimental approach, pioneered for renal
transplantation by our collaborators at the University of Cambridge, to reduce graft injury by improving the
metabolic state of the tissue. We hypothesize that this procedure can simultaneously be used to ameliorate IRI
and reduce rejection by delivery of siRNA to graft EC prior to organ implantation. We have selected tumor
necrosis factor receptor 1 (TNFR1) and its key adaptor protein, TRADD, as molecular targets for siRNA
knockdown in these experiments because these molecules mediate tumor necrosis factor- responses of EC
that promote inflammation and cell death, important processes in renal IRI, but the goal of this R21 is limited to
optimization of the effect of siRNA knockdown. siRNA delivery in the clinic is currently limited by incomplete
extent and short duration of knockdown, by inability to efficiently target the cells of interest and by effects of
inappropriate cellular targets. Here, we propose proof-of-principle studies to demonstrate that antibody-
conjugated, degradable polymer nanoparticles (NP) can be designed to overcome these limitations. Our
specific aims are: (1) to optimize formulation of multifunctional, degradable NPs using both established and
novel degradable polymers for siRNA loading, siRNA sustained release and mAb conjugation; (2) to identify
the best EC specific mAb or combination of mAb for binding and uptake of conjugated NP by cultured human
EC under flow in vitro at Yale and in deceased donor kidneys undergoing EVNP, the latter to be performed by
our collaborators at the University of Cambridge with resources independent of this R21 application;
Successful completion of these aims will provide proof-of-concept for an innovative approach to reduce
allograft rejection by ex vivo targeting the graft with novel drug delivery vehicles, sparing the host from the
need to excessive immunosuppression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium
-
批准号:10783379
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2023
-
负责人:JORDAN S POBER
-
依托单位:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
-
批准号:10353416
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2021
-
负责人:JORDAN S POBER
-
依托单位:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
-
批准号:10194232
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2021
-
负责人:JORDAN S POBER
-
依托单位:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
-
批准号:10197784
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2017
-
负责人:JORDAN S POBER
-
依托单位:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
-
批准号:10155842
-
项目类别:
-
资助金额:$2.94万
-
财政年份:2017
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9516109
-
项目类别:
-
资助金额:$37.24万
-
财政年份:2017
-
负责人:JORDAN S POBER
-
依托单位:
Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection
-
批准号:8693080
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2013
-
负责人:JORDAN S POBER
-
依托单位:
Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self-Assembly
-
批准号:8322816
-
项目类别:
-
资助金额:$24.91万
-
财政年份:2011
-
负责人:JORDAN S POBER
-
依托单位:
Controlled Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self
-
批准号:8138278
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2011
-
负责人:JORDAN S POBER
-
依托单位:
SCID Mouse: Human Xenograft Core
-
批准号:7608570
-
项目类别:
-
资助金额:$11.28万
-
财政年份:2008
-
负责人:JORDAN S POBER
-
依托单位:
SCID Mouse : Human Xenograft Core
-
批准号:7392297
-
项目类别:
-
资助金额:$9.84万
-
财政年份:2007
-
负责人:JORDAN S POBER
-
依托单位:
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells
-
批准号:7491181
-
项目类别:
-
资助金额:$42.78万
-
财政年份:2007
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9102509
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:8657086
-
项目类别:
-
资助金额:$39.78万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9335938
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:8529594
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells
-
批准号:7297613
-
项目类别:
-
资助金额:$42.36万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9759975
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:8296172
-
项目类别:
-
资助金额:$40.48万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Administration
-
批准号:7297631
-
项目类别:
-
资助金额:$6.72万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位: